Matthew C. Garrett Net Worth

The estimated Net Worth of Matthew C. Garrett is at least $4.6 Milion dollars as of 15 January 2020. Mr Garrett owns over 28,697 units of iRhythm Technologies Inc stock worth over $3,708,874 and over the last 8 years he sold IRTC stock worth over $65,615. In addition, he makes $826,034 as Advisor at iRhythm Technologies Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr Garrett IRTC stock SEC Form 4 insiders trading

Mr has made over 9 trades of the iRhythm Technologies Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 28,697 units of IRTC stock worth $420,124 on 15 January 2020.

The largest trade he's ever made was exercising 42,910 units of iRhythm Technologies Inc stock on 5 January 2018 worth over $176,789. On average, Mr trades about 10,903 units every 54 days since 2016. As of 15 January 2020 he still owns at least 49,564 units of iRhythm Technologies Inc stock.

You can see the complete history of Mr Garrett stock trades at the bottom of the page.

Mr. Matthew C. Garrett biography

Matthew C. Garrett is the Advisor at iRhythm Technologies Inc.

What is the salary of Mr Garrett?

As the Advisor of iRhythm Technologies Inc, the total compensation of Mr Garrett at iRhythm Technologies Inc is $826,034. There are 4 executives at iRhythm Technologies Inc getting paid more, with Kevin King having the highest compensation of $4,774,140.

How old is Mr Garrett?

Mr Garrett is 52, he's been the Advisor of iRhythm Technologies Inc since . There are 16 older and 7 younger executives at iRhythm Technologies Inc. The oldest executive at iRhythm Technologies Inc is Ralph Snyderman, 80, who is the Independent Director.

What's Mr Garrett's mailing address?

Matthew's mailing address filed with the SEC is 650 Townsend St # 500, San Francisco, CA 94103, USA.

Insiders trading at iRhythm Technologies Inc

Over the last 8 years, insiders at iRhythm Technologies Inc have traded over $124,847,276 worth of iRhythm Technologies Inc stock and bought 150,000 units worth $2,550,000 . The most active insiders traders include Holdings A/S Novo, Vijay K Lathi oraz Kevin M King. On average, iRhythm Technologies Inc executives and independent directors trade stock every 17 days with the average trade being worth of $1,872,546. The most recent stock trade was executed by Brice Bobzien on 9 August 2024, trading 1,372 units of IRTC stock currently worth $96,506.

What does iRhythm Technologies Inc do?

irhythm is a digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed by combining our wearable biosensing technology with cloud-based data analytics and machine- learning capabilities. our goal is to be the leading provider of first-line ambulatory electrocardiogram, or ecg, monitoring for patients at risk for arrhythmias. we have created a unique platform, zio by irhythm, which we believe allows physicians to diagnose many arrhythmias more quickly and efficiently than traditional technologies, avoiding multiple indeterminate tests, allowing for appropriate medical intervention and potentially avoiding more serious downstream medical events, including stroke.

Complete history of Mr Garrett stock trades at iRhythm Technologies Inc

iRhythm Technologies Inc executives and stock owners

iRhythm Technologies Inc executives and other stock owners filed with the SEC include:

• Kevin King,
  President, Chief Executive Officer, Director
• David Vort,
  Executive Vice President - Sales
• Mark Day,
  Executive Vice President of Research and Development
• Kevin M. King,
  Consultant & Director
• Matthew C. Garrett,
  Advisor
• Daniel G. Wilson,
  Exec. VP of Strategy, Corp. Devel. & Investor Relations
• Douglas J. Devine,
  COO, CFO & Sec.
• David A. Vort,
  Exec. VP of Sales & Chief Commercial Officer
• Mark J. Day Ph.D.,
  Exec. VP of R&D
• Abhijit Talwalkar,
  Independent Chairman of the Board
• Mark Rubash,
  Independent Director
• Raymond Scott,
  Independent Director
• Bruce Bodaken,
  Independent Director
• Ralph Snyderman,
  Independent Director
• Cathleen Noel Merz,
  Independent Director
• Douglas Devine,
  Chief Financial Officer
• Renee Budig,
  Independent Director
• Mazi Kiani,
  Sr. VP of Quality & Regulatory
• Dietra N. Jones,
  Exec. VP of Clinical Operations
• Reyna M. Fernandez,
  Exec. VP & Chief HR Officer
• Dr. Mintu P. Turakhia M.D.,
  Chief Medical Officer & Chief Scientific Officer
• Allan B. Wilsker,
  Exec. VP of Information Technology & Customer Service
• Patrick Michael Murphy J.D.,
  Gen. Counsel
• Quentin S. Blackford,
  Pres & CEO
• Judith C. Lenane,
  Chief Clinical Officer & Exec. VP of Operations
• Kaja J. Odegard,
  VP of HR
• Marga Ortigas-Wedekind,
  Exec. VP of Marketing
• Michael J. Coyle,
  Pres, CEO & Director
• Tiba Aynechi,
  Director
• Life Science Partners L P S...,
  
• Venture Partners Xi, Lp Cro...,
  
• Matthew C. Garrett,
  Chief Financial Officer
• Life Science Partners L P S...,
  
• Holdings A/S Novo,
  10% owner
• Clercq Casper L. De,
  Director
• Michael J Coyle,
  President and CEO
• Vijay K Lathi,
  Director
• Karim Karti,
  Former Chief Operating Officer
• Derrick Sung,
  EVP, Strat Corp Development
• Mojdeh Poul,
  Director
• Brian B Yoor,
  Director
• Karen Ling,
  Director
• Mervin Smith,
  EVP Strategic Business Ops
• Marc W. Rosenbaum,
  Chief Accounting Officer
• Daniel G. Wilson,
  EVP, Corp Dev Inv Rel
• Brice Bobzien,
  Chief Financial Officer
• Quentin S. Blackford,
  President and CEO
• Minang Turakhia,
  EVP, CMO & CSO
• Reyna M Fernandez,
  EVP, Chief HR Officer
• Chad Patterson,
  Chief Commercial Officer
• Sumi Shrishrimal,
  EVP, Chief Risk Officer
• Patrick Michael Murphy,
  CBO and CLO